The same group also applied subcellular resolved ST (Stereo‐seq) to identify key regulatory events at the tumor–immune interface that involve trafficking of amloid A1 and A2 and activation of tumor‐stemming JAK–STAT3 via CXCL6.172. This evidence concerns the gene CXCL6 and neoplasm.